Articles From: Algonquin Power & Utilities Corp. Enters an Agreement to Acquire New England Gas Company to Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results

OAKVILLE, ON , Feb.

China's Alibaba Group Holding Ltd.

Alibaba Group, China’s largest e-Commerce company, and MasterCard have signed a Memorandum of Understanding (MOU) to explore future collaboration in the area of e-Commerce.

China's Alibaba Group Holding Ltd.

HONG KONG --Chinese e-commerce giant Alibaba Group Holding Ltd.

China's biggest Internet companies are drawing up battle lines.

FORT MYERS, Fla., Feb.

FORT MYERS, Fla., Feb.

FORT MYERS, Fla., May 2, 2013 (GLOBE NEWSWIRE) -- Alico, Inc. ("Alico") (Nasdaq:ALCO) , an American agribusiness and land management company, announced that its Board of Directors, at a meeting held on May 2, 2013, declared a third quarter cash dividend in the amount of $0.08 per share on its outstanding common stock.

FORT MYERS, Fla., May 6, 2013 (GLOBE NEWSWIRE) -- Alico, Inc. ("Alico") (Nasdaq:ALCO) , an American agribusiness and land management company, today announced financial results for the second quarter and six months ended March 31, 2013.

FORT MYERS, Fla., Jan.

FORT MYERS, Fla., April 23, 2013 (GLOBE NEWSWIRE) -- Alico, Inc. (Nasdaq:ALCO) ("Alico"), a Florida-based agribusiness and land management company announced today that it will release its second quarter and six months of fiscal year 2013 results after the market closes on Monday, May 6, 2013.

AlienVault , the leading  Unified Security Management  provider committed to making security visibility complete, simple and affordable, today announced the appointment of Rita Selvaggi as Chief Marketing Officer (CMO). As CMO, Selvaggi will work closely with AlienVault’s executive team to align the global marketing, product, and sales organizations around the company’s goal of delivering security visibility to the under-served mid-market.

http://media.marketwire.com/attachments/201208/50314_Align_Technology_logo95.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=980152&ProfileId=051205&sourceType=1 SAN JOSE, CA --

http://media.marketwire.com/attachments/201208/50314_Align_Technology_logo95.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1008506&ProfileId=051205&sourceType=1 SAN JOSE, CA --

http://media.marketwire.com/attachments/201208/50314_Align_Technology_logo95.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=979885&ProfileId=051205&sourceType=1 SAN JOSE, CA --

http://media.marketwire.com/attachments/201208/50314_Align_Technology_logo95.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=987578&ProfileId=051205&sourceType=1 SAN JOSE, CA --

http://media.marketwire.com/attachments/201208/50314_Align_Technology_logo95.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=990127&ProfileId=051205&sourceType=1 SAN JOSE, CA and SINGAPORE --

http://media.marketwire.com/attachments/201208/50314_Align_Technology_logo95.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1002131&ProfileId=051205&sourceType=1 SAN JOSE, CA --

Alimentation Couche-Tard announces its results for the third quarter of fiscal 2013 Canada NewsWire Highlights of the Third Quarter of fiscal 2013 Statoil Fuel & Retail ASA ("Statoil Fuel & Retail") Acquisition of Statoil Fuel & Retail On June 19, 2012, the Corporation acquired 81.2% of the 300,000,000 issued and outstanding shares of Statoil Fuel & Retail for a cash consideration of 51.20 Norwegian Kroners ("NOK") per share for a total amount of NOK 12.47 billion or approximately $2.10 billion through a voluntary public offer (the "offer"). From June 22, 2012 to June 29, 2012, the Corporation acquired 53,238,857 additional shares of Statoil Fuel & Retail for a cash consideration of NOK 51.20 per share, totalling NOK 2.73 billion or approximately $0.45 billion, increasing its participation to 98.9%. Having reached a shareholding of more than 90%, on June 29, 2012, in accordance with Norwegian laws, Couche-Tard initiated the

Diluted net earnings per share of the third quarter are US$0.75 compared to US$0.48 last year, a 56.3% increase.

ILUVIEN now available in Germany as a new treatment for chronic diabetic macular edema ATLANTA , May 7, 2013 /PRNewswire/-- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that ILUVIEN ® , the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema (DME), is now commercially available in Germany .

Simple Patient Access Scheme has been submitted to NICE for rapid review       ATLANTA , April 29, 2013 /PRNewswire/ -- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that ILUVIEN ® , the first sustained release pharmaceutical product for the treatment of chronic diabetic macular edema (DME), is now available in the United Kingdom .

PDUFA goal date set for October 17, 2013 ATLANTA , May 1, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its recent resubmission of the New Drug Application (NDA) for ILUVIEN ® has been acknowledged as received by the U.S. Food and Drug Administration (FDA) as a complete class 2 response to the FDA's November 2011 letter and that a new Prescription Drug User Fee Act (PDUFA) goal date of October 17, 2013 has been established.

ATLANTA , Feb.

Company Begins Selling ILUVIEN in the United Kingdom and Germany During Second Quarter of 2013 FDA PDUFA Goal Date of October 17, 2013 Set for ILUVIEN Alimera Will Host a Conference Call at 4:30 PM ET Today ATLANTA , May 9, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the first quarter ended March 31, 2013 .

Company to Begin Generating Revenue in Second Quarter of 2013 Alimera Will Host a Conference Call at 4:30 PM ET Today ATLANTA , March 21, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter ended December 31, 2012 .

ATLANTA , May 8, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that its United Kingdom subsidiary, Alimera Sciences Limited, has entered into a Loan and Security Agreement with Silicon Valley Bank (SVB) providing for a term loan in the principal amount of $5 million and up to an additional $15 million under a working capital line of credit.

ATLANTA , May 3, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its first quarter fiscal year 2013 financial results after the market close on Thursday, May 9, 2013 .

ATLANTA , March 11, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2012 financial results after the market close on Thursday, March 21, 2013 .